Warfarin testing company raises funds

Microvisk Technologies, developer of a handheld device to monitor blood clotting in patients taking the drug warfarin, has secured £2.5 million.


Microvisk Technologies, developer of a handheld device to monitor blood clotting in patients taking the drug warfarin, has secured £2.5 million.

Microvisk Technologies, developer of a handheld device to monitor blood clotting in patients taking the drug warfarin, has secured £2.5 million.

The money was raised through a rights issue to existing investors in a round that was oversubscribed and completed in four weeks.

Participants in the fundraising included Oxford Technology Management, Porton Capital, Midven, the Rainbow Seed Fund, Finance Wales and private investors. US-based investor New Hill Management also joined the round.

Microvisk was spun out from the Science and Technology Facilities Council, a government-backed body supporting scientific research.

Its prototype device uses sensors to work out the clotting speed of blood from a finger prick sample, displaying the results on a handheld reader.

Warfarin is used by an estimated 7 million people in the Western world. Currently, patients must have regular tests at their doctor’s surgery to ensure they receive the correct dose.

Nick Britton

Nick Britton

Nick was the Managing Editor for growthbusiness.co.uk when it was owned by Vitesse Media, before moving on to become Head of Investment Group and Editor at What Investment and thence to Head of Intermediary...

Related Topics